デフォルト表紙
市場調査レポート
商品コード
1671847

自己細胞療法市場:製品タイプ別、用途別、技術別、エンドユーザー別、地域別

Autologous Cell Therapy Market, By Product Type, By Application, By Technology, By End User, By Geography


出版日
ページ情報
英文 155 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
自己細胞療法市場:製品タイプ別、用途別、技術別、エンドユーザー別、地域別
出版日: 2025年01月07日
発行: Coherent Market Insights
ページ情報: 英文 155 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の自己細胞療法市場は、2025年には55億1,000万米ドルと推定され、2032年には223億米ドルに達すると予測され、2025年から2032年までのCAGRは22.1%を示すと予測されます。

レポート範囲 レポート詳細
基準年 2024 2025年の市場規模 55億1,000万米ドル
実績データ 2020年から2024年まで 予測期間 2025年から2032年
予測期間:2025年~2032年 CAGR: 22.10% 2032年の価値予測 223億米ドル
図.自己細胞療法市場シェア(%)、地域別、2025年
Autologous Cell Therapy Market-IMG1

世界の自己細胞療法市場は近年著しい成長を遂げています。自己細胞療法は、患者自身の体内から幹細胞や他の種類の細胞を採取し、様々なプロセスを通じて改変または拡大し、同じ患者に注入して病気を治療するものです。がんや神経疾患のような複雑な疾患を、免疫原性の懸念を最小限に抑えながら治療するための代替的な治療アプローチを提供します。慢性疾患の有病率の上昇、個別化医療に対する需要の高まり、同種細胞に対する自己細胞の優位性などが、今後自己細胞療法の需要を促進すると予想される主な要因です。しかし、市場開発と製造に伴うコスト高と規制上の課題が、市場にとっての大きな障壁となっています。

市場力学:

世界の自己細胞療法市場は、慢性疾患を発症しやすい高齢者人口の増加、製品開発を促進するための公的・民間企業からの投資の増加、個別化治療オプションに対する需要の高まりによって牽引されています。しかし、高い開発コスト、複雑な製造プロセス、厳格な規制方針が、予測期間中の市場成長を抑制すると予測されています。新たな適応症に対する自己細胞療法の有効性と安全性を評価する様々な臨床試験が進行中であり、革新的な製造技術の開発は、既存企業だけでなく新規参入企業にも大きなビジネスチャンスをもたらしています。主要企業は、これらの治療法の応用を拡大するために学術研究機関と協力しています。アジア太平洋地域は、中国やインドなどの主要国におけるヘルスケア・インフラの成長とヘルスケア支出の増加により、有利な市場機会をもたらしています。

本調査の主な特徴

本レポートでは、世界の自己細胞療法市場を詳細に分析し、2024年を基準年とした予測期間(2025-2032年)の市場規模およびCAGRを掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の発売や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。

企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の自己細胞療法市場の主要企業をプロファイルしています。

主な企業は、Bristol Myers Squibb、Novartis、Gilead Sciences、Kite Pharma、Celgene、Amgen、武田薬品工業、Merck KGaA、Bluebird Bio、Celyad Oncology、Adaptimmune Therapeutics、Allogene Therapeutics、Athersys, Inc.、BrainStorm Cell Therapeutics、Sorrento Therapeuticsなどです。

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

この調査レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。

利害関係者は、世界の自己細胞療法市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学、規制、動向分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • PORTERの分析
  • 合併と買収のシナリオ
  • 業界動向

第4章 世界の自己細胞療法市場、製品タイプ別、2020年~2032年

  • 細胞ベースの治療法
  • 組織ベースの治療法
  • 遺伝子治療

第5章 世界の自己細胞療法市場、用途別、2020年-2032年

  • 腫瘍学
  • 心血管疾患
  • 神経疾患
  • 整形外科疾患
  • 自己免疫疾患
  • 創傷治癒

第6章 世界の自己細胞療法市場、技術別、2020年-2032年

  • 幹細胞療法
  • CAR T細胞療法
  • T細胞受容体(TCR)療法
  • 人工多能性幹細胞(iPSC)

第7章 世界の自己細胞療法市場、エンドユーザー別、2020年-2032年

  • 病院
  • 調査機関
  • バイオテクノロジー企業
  • 製薬会社
  • その他

第8章 世界の自己細胞療法市場、地域別、2020年-2032年

  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第9章 競合情勢

  • Bristol Myers Squibb
  • Novartis
  • Gilead Sciences
  • Kite Pharma
  • Celgene
  • Amgen
  • Takeda Pharmaceutical Company
  • Merck KGaA
  • Bluebird Bio
  • Celyad Oncology
  • Adaptimmune Therapeutics
  • Allogene Therapeutics
  • Athersys, Inc.
  • BrainStorm Cell Therapeutics
  • Sorrento Therapeutics

第10章 アナリストの推奨事項

  • 運命の輪
  • アナリストの見解
  • 一貫した機会マップ

第11章 参考文献と調査手法

  • 参考文献
  • 調査手法
  • 出版社について
目次
Product Code: CMI7696

The Global Autologous Cell Therapy Market is estimated to be valued at USD 5.51 Bn in 2025 and is expected to reach USD 22.30 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 22.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 5.51 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 22.10% 2032 Value Projection: USD 22.30 Bn
Figure. Autologous Cell Therapy Market Share (%), By Region, 2025
Autologous Cell Therapy Market - IMG1

The global autologous cell therapy market has been witnessing significant growth in the recent years. Autologous cell therapy involves the collection of stem cells or other types of cells from patient's own body, modifying or expanding them through various processes and infusing back to the same patient to treat diseases. It provides an alternative therapeutic approach to treat complex diseases like cancer and neurological disorders with minimal immunogenicity concerns. Rising prevalence of chronic diseases, growing demand for personalized medicine, and advantages of autologous cells over allogeneic cells are some key factors expected to propel demand for autologous cell therapies going forward. However, high costs associated with development and manufacturing along with regulatory challenges are major barriers to the market.

Market Dynamics:

The global autologous cell therapy market is driven by rising geriatric population vulnerable to develop chronic diseases, increasing investments from public and private players to expedite product development, and growing demand for personalized treatment options. However, high development costs, complex manufacturing processes, and stringent regulatory policies are projected to restrain the market growth during the forecast period. Various ongoing clinical trials evaluating efficacy and safety of autologous cell therapies for new indications and development of innovative manufacturing technologies present significant opportunities for existing as well as new market players. Key players are collaborating with academic research institutions to expand applications of these therapies. Asia Pacific presents lucrative market opportunities with growing healthcare infrastructure and increasing healthcare spending in major countries like China and India.

Key Features of the Study:

This report provides in-depth analysis of the global autologous cell therapy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autologous cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Bristol Myers Squibb, Novartis, Gilead Sciences, Kite Pharma, Celgene, Amgen, Takeda Pharmaceutical Company, Merck KGaA, Bluebird Bio, Celyad Oncology, Adaptimmune Therapeutics, Allogene Therapeutics, Athersys, Inc., BrainStorm Cell Therapeutics, and Sorrento Therapeutics

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global autologous cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autologous cell therapy market

Market Segmentation

  • Product Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Cell-based therapies
    • Tissue-based therapies
    • Gene therapies
  • Application Insights (Revenue, USD Bn, 2020 - 2032)
    • Oncology
    • Cardiovascular diseases
    • Neurological disorders
    • Orthopedic disorders
    • Autoimmune diseases
    • Wound healing
  • Technology Insights (Revenue, USD Bn, 2020 - 2032)
    • Stem cell therapy
    • CAR T-cell therapy
    • T-cell receptor (TCR) therapy
    • Induced pluripotent stem cells (iPSCs)
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals
    • Research institutes
    • Biotechnology companies
    • Pharmaceutical companies
    • Others
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Bristol Myers Squibb
    • Novartis
    • Gilead Sciences
    • Kite Pharma
    • Celgene
    • Amgen
    • Takeda Pharmaceutical Company
    • Merck KGaA
    • Bluebird Bio
    • Celyad Oncology
    • Adaptimmune Therapeutics
    • Allogene Therapeutics
    • Athersys, Inc.
    • BrainStorm Cell Therapeutics
    • Sorrento Therapeutics

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Autologous Cell Therapy Market, By Product Type
    • Global Autologous Cell Therapy Market, By Application
    • Global Autologous Cell Therapy Market, By Technology
    • Global Autologous Cell Therapy Market, By End User
    • Global Autologous Cell Therapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Autologous Cell Therapy Market, By Product Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Cell-based therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Tissue-based therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Gene therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Autologous Cell Therapy Market, By Application, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cardiovascular diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Neurological disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Orthopedic disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Autoimmune diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Wound healing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Autologous Cell Therapy Market, By Technology, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Stem cell therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • CAR T-cell therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • T-cell receptor (TCR) therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Induced pluripotent stem cells (iPSCs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Autologous Cell Therapy Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Research institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Biotechnology companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pharmaceutical companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Autologous Cell Therapy Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • Bristol Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Gilead Sciences
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kite Pharma
  • Celgene
  • Amgen
  • Takeda Pharmaceutical Company
  • Merck KGaA
  • Bluebird Bio
  • Celyad Oncology
  • Adaptimmune Therapeutics
  • Allogene Therapeutics
  • Athersys, Inc.
  • BrainStorm Cell Therapeutics
  • Sorrento Therapeutics

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us